Acumen pharmaceuticals reports second quarter 2023 financial results and business highlights

Charlottesville, va. and carmel, ind., aug. 08, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today reported financial results for the second quarter of 2023 and provided a business update.
ABOS Ratings Summary
ABOS Quant Ranking